Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis

Clinical and Experimental Immunology

Volumn 179, Issue 3, 2015, Pages 500-508

  Elvington, M ^a   Schepp Berglind, J ^a   Tomlinson, S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Colon; Complement; Inflammation; Inflammatory bowel disease

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2; DEXTRAN SULFATE; MANNOSE BINDING LECTIN; OPSONIN; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; CR2-FH PROTEIN; HYBRID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CHRONIC DISEASE; COLITIS; COLON INJURY; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNITY; INFECTION; INTESTINAL FIBROSIS; LAMINA PROPRIA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RELAPSE; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COMPLEMENT ALTERNATIVE PATHWAY; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INTESTINE; KNOCKOUT MOUSE; MOLECULARLY TARGETED THERAPY; MUCOSAL IMMUNITY;

ANIMALS; CHRONIC DISEASE; COLITIS; COMPLEMENT C3; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INTESTINES; MANNOSE-BINDING LECTIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; RECEPTORS, COMPLEMENT 3D; RECOMBINANT FUSION PROTEINS;

EID: 84922767834     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12464     Document Type: Article

References (34)

1. Ueki T, Mizuno M, Uesu T etal. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996; 104:286-292.
2. Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 1989; 30:361-366.
3. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003; 171:5514-5520.
4. Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98:1264-1271.
5. Halstensen TS, Brandtzaeg P. Local complement activation in inflammatory bowel disease. Immunol Res 1991; 10:485-492.
6. Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med 1990; 322:1345-1349.
7. Scheinin T, Bohling T, Halme L, Kontiainen S, Bjorge L, Meri S. Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease. Hum Pathol 1999; 30:1427-1430.
8. Berstad AE, Brandtzaeg P. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 1998; 42:522-529.
9. Uesu T, Mizuno M, Inoue H, Tomoda J, Tsuji T. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest 1995; 72:587-591.
10. Wende E, Laudeley R, Bleich A etal. The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice. PLOS ONE 2013; 8:e62257.
11. Jain U, Woodruff TM, Stadnyk AW. The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. Br J Pharmacol 2013; 168:488-501.
12. Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, Tomlinson S. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol 2012; 188:6309-6318.
13. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004; 172:3836-3841.
14. Deguchi Y, Andoh A, Inatomi O etal. Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med 2005; 16:605-608.
15. Lu F, Fernandes SM, Davis AE III. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2010; 298:G878-883.
16. Johswich K, Martin M, Bleich A etal. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1812-1823.
17. Huber-Lang M, Sarma JV, Zetoune FS etal. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682-687.
18. Krisinger MJ, Goebeler V, Lu Z etal. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120:1717-1725.
19. Muller S, Schaffer T, Flogerzi B etal. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut 2010; 59:1493-1500.
20. Aomatsu T, Imaeda H, Takahashi K etal. Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice. J Clin Biochem Nutr 2013; 52:72-75.
21. Chen G, Yang Y, Gao X etal. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest 2011; 91:472-483.
22. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008; 181:8068-8076.
23. Atkinson C, Song H, Lu B etal. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005; 115:2444-2453.
24. Hall LJ, Faivre E, Quinlan A, Shanahan F, Nally K, Melgar S. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig Dis Sci 2011; 56:79-89.
25. Bento AF, Leite DF, Marcon R etal. Evaluation of chemical mediators and cellular response during acute and chronic gut inflammatory response induced by dextran sodium sulfate in mice. Biochem Pharmacol 2012; 84:1459-1469.
26. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol 2005; 288:G1328-1338.
27. Alex P, Zachos NC, Nguyen T etal. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2008; 15:341-352.
28. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108:1268-1276.
29. de Buck van Overstraeten A, Wolthuis A, D'Hoore A. Surgery for Crohn's disease in the era of biologicals: a reduced need or delayed verdict? World J Gastroenterol 2012; 18:3828-3832.
30. Dorn I, Schlenke P, Mascher B, Stange EF, Seyfarth M. Lamina propria plasma cells in inflammatory bowel disease: intracellular detection of immunoglobulins using flow cytometry. Immunobiology 2002; 206:546-557.
31. Niess JH. Role of mucosal dendritic cells in inflammatory bowel disease. World J Gastroenterol 2008; 14:5138-5148.
32. Abe K, Nguyen KP, Fine SD etal. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA 2007; 104:17022-17027.
33. Noronha AM, Liang Y, Hetzel JT etal. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol 2009; 86:1007-1016.
34. Rieder F, Brenmoehl J, Leeb S, Scholmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007; 56:130-139.